UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$378.07Price
Low $230.47
Mid $339.99
High $449.63
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.
Cycle upside
Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.
UNH (UNH)'s margin set covers gross margin, operating margin, net margin, and free-cash-flow margin. The five-year trajectory is plotted so the reader can separate cyclical noise from secular trend.
Margin expansion or compression is read against the revenue base: if operating margin expands while revenue grows, that is operating leverage. If gross margin compresses, the cause (mix shift, input costs, pricing) is annotated in the numbers analysis.
Peer-relative margin context lives on the parent peers tab, which sets UNH's gross, operating, and net margins against four to five named peers from the same archetype and sector.
FCF margin is reported alongside operating margin so the reader can spot cases where capex intensity changes the cash-conversion read even when reported profitability is steady.
FAQ
UNH — frequently asked questions
Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Our composite fair-value range for UNH is $230–$450, with a midpoint of $340. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for UNH's archetype.
Our current rating for UNH is Reduce with a confidence score of 88/100. We rate UNH a Reduce (or Hold for strictly long-term, tax-sensitive accounts). The heavily penalized $339.99 midpoint reflects near-term operational realities. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for UNH are: Permanent MA Rate Cuts; Runaway Medical Inflation; Antitrust Optum Breakup. The single biggest risk is Permanent MA Rate Cuts: Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.
Our current rating for UNH is Reduce, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($230–$450) versus the current price of $378.
UNH is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for UNH.